Jubira CV 10 Capsule is a combination medication containing Rosuvastatin 10 mg and Clopidogrel 75 mg, indicated for the management of cardiovascular conditions requiring both lipid-lowering and antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby aiding in the prevention of atherosclerosis and related cardiovascular events. Clopidogrel, a thienopyridine class antiplatelet agent, inhibits platelet aggregation by irreversibly blocking the P2Y12 component of ADP receptors on platelet surfaces, reducing the risk of thrombotic events such as myocardial infarction and stroke. The combined use of these agents in Jubira CV 10 Capsule is particularly beneficial in patients with established coronary artery disease, peripheral arterial disease, or those at high risk of cardiovascular events, providing synergistic effects in reducing morbidity and mortality. This fixed-dose combination enhances patient compliance by simplifying treatment regimens. Jubira CV 10 Capsule should be administered under medical supervision, with periodic monitoring of lipid profiles, liver function tests, and platelet counts to ensure efficacy and safety. Contraindications include active bleeding, severe liver impairment, and hypersensitivity to either component.